Facebook
Twitter
LinkedIn
Forward
Identifying and Treating NK: Have You Got the Nerve? (Virtual CE Symposium)
To register for the symposium, please click Register/Take Course.
Friday, November 8, 2024
3:30 PM – 5:00 PM PT | 4:30 PM – 6:00 PM MT
5:30 PM – 7:00 PM CT | 6:30 PM – 8:00 PM ET
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Integrate corneal sensitivity testing into practice to identify neurotrophic keratitis
- Select appropriate treatment for patients with neurotrophic keratitis using clinical evidence
Faculty
 | Paul Karpecki, OD, FAAO (Chair) Director, Cornea and External Disease Kentucky Eye Institute Lexington, Kentucky Associate Professor University of Pikeville School of Optometry Pikeville, Kentucky |
 | Jessilin Quint, OD, MBA, FAAO Co-Owner Smart Eye Care Augusta, Maine Associate Professor Indiana University School of Optometry Bloomington, Indiana |
 | Walter O. Whitley, OD, MBA, FAAO Director, Optometric Services Virginia Eye Consultants Virginia Beach, Virginia |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Paul Karpecki, OD, is a consultant for AbbVie Inc, AdOM Optical Technologies Ltd, AesculaTech, AI Optics, Alcon, Aldeyra Therapeutics, Ametek, Inc, Amgen Inc*, Apellis Pharmaceuticals, Aramis Biosciences, Astellas Pharma Inc, Atlas Medical GmbH, Aurion Biotechnologies, Avellino*, Azura Ophthalmics, Bausch & Lomb Incorporated, Bio-Tissue, Bruno Vision, Dompé US Inc, Essilor of America, Inc, Eyenovia, Inc*, Harrow, Inc, Hilco Vision, iCare USA Inc, Kiora Pharmaceuticals, Inc*, Konan Medical USA, Inc*, Lentechs, LKC Technologies, Inc, Mitotech*, Neurolens, Novaliq GmbH*, Novartis Pharmaceuticals Corporation*, OASIS Medical, OCULUS, Inc, OCuSOFT Inc, OcuTerra Therapeutics*, Orasis Pharmaceuticals, Reichert, Inc, Rendia, Inc, RxSIGHT, RVL Pharmaceuticals, Inc*, Samsara Vision, Inc, ScienceBased Health, Scope, Sentiss Pharma Pvt Ltd, Sight Sciences, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Sydnexis Inc, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc*, Topcon Medical Systems, Inc, Trukera, Twenty Twenty Therapeutics, LLC*, Vial, Viatris, Visant Medical, Inc*, Visus Therapeutics*, Vital Tears LLC, WebMD LLC, and Zeiss; is an advisory board member of Silk Technologies Ltd*, is a contracted researcher for Amber Ophthalmics and Lumibird; has stock options that have not been exercised in BlephEx, Eyedaptic Inc, Eyedetec Medical, Eyesafe Inc, Hue.AI, iVeena Delivery Systems, Ocuphire Pharma, Omega Ophthalmics, Ophthalmic Resources Partners, Silk Technologies Ltd*, TearClear, and Visant Medical, Inc*; and receives honorarium from Mallinckrodt.
Jessilin Quint, OD, MBA, is a consultant for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Eyenovia Vision, Lumenis, Ocuphire Pharma, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Tarsus Pharmaceuticals, Inc, and Viatris Inc; and is on the speakers bureau for AbbVie Inc, Alcon, and Bausch & Lomb Incorporated.
Walter O. Whitley, OD, MBA, is a consultant for AbbVie Inc, Alcon, Aldeyra Therapeutics, Apellis Pharmaceuticals, Astellas Pharma Inc, Bruder Healthcare, Dompé US, Inc, Eyenovia, Inc, Heru, Inc, Mediprint, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Regener-Eyes, Tarsus Pharmaceuticals, Inc, and Thea Pharma Inc; is an advisory board member of AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Bruder Healthcare, Oyster Point Pharma, Inc, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Visus Therapeutics; is on the speakers bureau for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and is a contracted researcher for Heru, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
Accreditation Statement
COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: XXXXXX (Synchronous Virtual)
COPE Course Category: Treatment and Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number XXXXXX, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.
This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 324.1
Available Credit
- 1.50 COPE
To register for this symposium, please select the purple Take course button. You will receive an email confirmation. If you do not receive a confirmation, please check your spam folder or email info@mededicus.com.
We look forward to your participation on November 8!